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Video abstract

Introduction: Heat/capsaicin skin sensitization is a well-characterized human experimental
model to induce hyperalgesia and allodynia. Using this model, gabapentin, among other drugs,
was shown to significantly reduce cutaneous hyperalgesia compared to placebo. Since the larger
thermal probes used in the original studies to produce heat sensitization are now commercially
unavailable, we decided to assess whether previous findings could be replicated with a currently
available smaller probe (heated area 9 cm2 versus 12.5–15.7 cm2).
Study design and methods: After Institutional Review Board approval, 15 adult healthy
volunteers participated in two study sessions, scheduled 1 week apart (Part A). In both sessions,
subjects were exposed to the heat/capsaicin cutaneous sensitization model. Areas of hypersensitivity to brush stroke and von Frey (VF) filament stimulation were measured at baseline and
after rekindling of skin sensitization. Another group of 15 volunteers was exposed to an identical
schedule and set of sensitization procedures, but, in each session, received either gabapentin
or placebo (Part B).
Results: Unlike previous reports, a similar reduction of areas of hyperalgesia was observed in
all groups/sessions. Fading of areas of hyperalgesia over time was observed in Part A. In Part B,
there was no difference in area reduction after gabapentin compared to placebo.
Conclusion: When using smaller thermal probes than originally proposed, modifications of
other parameters of sensitization and/or rekindling process may be needed to allow the heat/
capsaicin sensitization protocol to be used as initially intended. Standardization and validation
of experimental pain models is critical to the advancement of translational pain research.
Keywords: experimental pain model, hyperalgesia, peripheral sensitization, central
sensitization
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A reliable method to produce hyperalgesia and allodynia in human healthy volunteers
could have a crucial role in the development of novel analgesic compounds by helping
to bridge the gap between animal pain models and chronic pain patients.1,2 Hyperalgesia
and allodynia are common symptoms experienced in chronic pain syndromes3,4 and
are thought to depend on central nervous system sensitization, which is maintained
both by central mechanisms and ongoing peripheral stimuli.3–8 However, creating the
experimental conditions to reliably induce central sensitization and test the reversal
of established hyperalgesia is a complex task.9 The experimental model must be safe,
tolerable, and induce sensitization lasting long enough to allow testing of both prevention of hyperalgesia and reversal of established hypersensitivity without creating
permanent damage.
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One well characterized human experimental model of
cutaneous sensitization is the heat/capsaicin model.1,10 This
method uses the initial application of heat with a Peltier-type
thermal probe, then topical capsaicin cream, and subsequent
periodic thermal rekindling procedures to induce stable,
reproducible, and long-lasting (up to 4 hours) hyperalgesia
and secondary hypersensitivity in healthy human volunteers
and patients.1,2,10–16
One advantage of the heat/capsaicin model is the ability to generate hypersensitivity of sufficient duration to test
the onset and magnitude of drug analgesia without creating unacceptable discomfort, tissue injury, or long-lasting
effects.1,10,17 The heat/capsaicin sensitization model has been
applied successfully to demonstrate the ability of gabapentin,
among other drugs, to reduce cutaneous hyperalgesia. These
encouraging results, obtained with gabapentin, which is
clinically effective in treating neuropathic pain, proved that
the model could be used to predict clinical antihyperalgesic
efficacy.16,18,19 However, the reproducibility of all experimental pain models is influenced by multiple factors that
may affect within-day and between-day variability of the
subjects’ responses,17,20,21 and practical and logistical issues
may limit the consistency of results between observers and/
or laboratories.
The size of the area directly stimulated with heat and
capsaicin (area of “primary hyperalgesia”), and the resulting
size of the surrounding area of secondary hyperalgesia may
be critical factors in the reproducibility and applicability
of this model.20,22 When first reported, the heat/capsaicin
sensitization model used thermal stimulators with a heated
surface area of 12.5–15.7 cm2.1,2,10–12,15,16 The heat/capsaicin
model, as originally proposed, has become widely popular
and extensively utilized in research; the methods have been
reported in publications, lectures, and refresher courses at
international meetings.1,10,23,24 However, since publication
of the original report, the thermal probes that were utilized
are no longer commercially available. The largest Peltier
probe that is currently available has a heated surface area
of 9 cm2.
As the intensity of the stimulus used to induce the cutaneous hyperalgesia has been shown to affect both extent and
duration of the hyperalgesia,25,26 using the smaller thermode
(9 cm2) may affect the size and duration of the area of secondary hyperalgesia both by heating a smaller area of skin and by
providing a smaller contact surface to capsaicin cream (in this
model the area covered with capsaicin cream corresponds to
the thermode outline). This prompted us to question the possibility to reliably reproduce the model with a smaller area
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of peripheral sensitization. We knew that some researchers
had been able to reproduce heat/capsaicin sensitization with
smaller Peltier probes by utilizing modified procedures. The
original papers by Petersen and Dirks1,10 were quoted as a
source of the model in multiple studies by different groups
in which, however, the protocol was significantly modified
from the original, with different exposure time to capsaicin
and/or different procedures of application or maintenance
of the stimulus.27–30
Prior studies of analgesic responsiveness should be replicated before adopting the 9 cm2 thermal probe as the standard
for inducing heat/capsaicin cutaneous sensitization with this
model, and, if a different heat/capsaicin model needs to be
proposed as a standard, this would need to be validated on
the basis of rigorous observations. The sequential application
of heat and capsaicin will not always or necessarily produce
reliable and stable sensitization. It is not known what are the
essential elements of a model that associates heat and capsaicin to consistently create long lasting cutaneous sensitization;
these factors may vary interindividually and also depend on
the stimulation site and the outcomes observed. Using the
9 cm2 Peltier thermode to induce cutaneous sensitization,
the present study investigated the reproducibility of the heat/
capsaicin model as originally proposed1,10,16 by assessing:
a) the size and duration of secondary hyperalgesia; and b) the
antihyperalgesic response to a single oral dose of 1,200 mg
gabapentin (the same single dose of gabapentin that had
significantly decreased areas of hyperalgesia produced with
the original heat/capsaicin model compared to placebo).16

Materials and methods
Study subjects and design
The study was conducted in accordance with ethical principles of Good Clinical Practice and the Declaration of
Helsinki and its guidelines, and approved by Washington
University in St Louis Institutional Review Board.
Subjects provided written informed consent after the
study procedures were explained and their questions were
answered, and before study procedures were initiated. A list
of the inclusion and exclusion criteria, which were identical to
the criteria utilized in the original study that we were seeking
to replicate,16 is provided in Table 1, and demographic data
are shown in Table 2.
In a screening/training session preceding the first study
session, subjects were familiarized with the study procedures,
including the induction of sensitization with sequential application of heat and capsaicin (Figure 1A). During the first
study session, heat/capsaicin sensitization was induced and
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Male or nonpregnant, non-nursing female
2. 18–50 years old
3. Good general health with no remarkable medical conditions
(eg, liver, kidney, heart, or lung failure)
4. Body mass index between 20–33
5. Unmedicated (excludes contraceptives)
6. Willing to comply with study guidelines as outlined in protocol
7. Willing to provide informed consent
Exclusion criteria
1. Anatomical malformation of upper extremities
2. Status post recent trauma or chronic lesions on either forearm
3. Medication use (excludes contraceptives)
4. History of allergy or intolerance to capsaicin
5. History of allergy or intolerance to gabapentin
6. History of addiction to drugs or alcohol (prior or present addiction
or treatment for addiction)
7. History of chronic pain syndromes
8. Pregnant and nursing females
9. Heat Pain Detection Threshold greater than 47°C at baseline
10. Unable to achieve cutaneous sensitization with heat/capsaicin during
the training session

maintained by rekindling the stimulation site with heat four
times at regular intervals over the 4 hour study day. Areas of
secondary allodynia, and hyperalgesia to foam brush and VF
filament (primary outcomes); heat pain detection threshold
(HPDT) in the stimulation site (secondary outcomes); and the
painfulness of thermal stimulation (PTS) on nonsensitized
skin (secondary outcomes) were determined multiple times
during the study day. In all the study sessions, measurements
were performed before the induction of sensitization (M0 in
Figure 1B), after the first rekindling (RK1) (M1 in Figure 1B)
and after the fourth rekindling (RK4) (M2 in Figure 1B). The
study consisted of two parts:
Part A evaluated the natural history of sensory changes
following heat/capsaicin sensitization. Subjects in this group
underwent the procedures and measurements described above
during two study sessions separated by at least 1 week to
allow the skin to recover between sessions. In this group
Table 2 Study subjects’ demographics
Part A – control group (15 subjects)
Male (n): 7
 Age (years): 30(±8)
Race/ethnicity: White/Caucasian, n=13; African-American, n=1; Asian, n=1
Body mass index 25.6(±3.6)
Part B – treatment group (15 subjects)
Male (n): 7
 Age (years): 26(±3)
Race/ethnicity: White/Caucasian, n=15
Body mass index 26.4(±3)

Journal of Pain Research 2013:6
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only, additional area, HPDT, and PTS measurements were
repeated after RK2 and after RK3 to better follow the sensory changes. Subjects in Part A will be referred to as the
“control group”.
Part B was a double-blind, randomized, crossover study
in healthy volunteers to evaluate the response to gabapentin
using the heat/capsaicin model. On the first study session,
subjects were randomly assigned to receive a single oral
dose of gabapentin (1,200 mg) or placebo immediately after
induction of the heat/capsaicin sensitization as previously
described by Dirks et al.16
Outcome measures were collected as described above
(baseline, pre-drug and post-drug; for detail see Figure 1B).
During the second study session, subjects underwent the
same procedures but received the treatment that they had not
received during their first session. Sessions were 1 week apart
to allow washout of the treatment administered in the first
session. Areas obtained after gabapentin/placebo administration (M2 in Figure 1B) were compared to postsensitization
baseline areas (M1 in Figure 1B) and the results obtained with
gabapentin and placebo were compared. Subjects in Part B
will be referred to as the “gabapentin/placebo group”.
Sample size estimate was based on the previously published between-days coefficients of variation of the areas of
hyperalgesia obtained with this model.1 In the methodological study aimed at validating the heat/capsaicin model,1 the
authors calculated sample sizes needed to detect treatment
differences with this model, based on the coefficients of variation of areas of hyperalgesia within-day and between-day.
Assuming for our study the same coefficients of variation,
and planning a between-days comparison and a cross-over
design, we recalculated the sample size to obtain a probability
of 80% that the study could detect a treatment difference at
a two-sided 0.05 significance level, if the true difference in
area reduction between treatments (gabapentin and placebo)
was at least 30% (in the original study, comparing gabapentin and placebo with this model, the observed difference in
area reduction was about 70%). Our sample size calculation
indicated that 15 subjects were necessary in the treatment
group. An equal number of subjects were enrolled in the
control group for comparison.
Forty-nine subjects provided written consent and were
enrolled in the study. Seventeen subjects did not meet
inclusion criteria during the screening session and two
more were excluded during the study as they met exclusion criteria after enrollment. The remaining 30 subjects
completed Part A (n=15) or Part B (n=15) of the study. The
15 subjects who took part in Part B of the study were assigned
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A) Timeline of screening/training day procedures
Start HC

M-test
(40 minutes)

0 minutes

60 minutes
Discharge

Presensitization
baseline M0
(–20 minutes)

B) Timeline of study day procedures – sessions 1 and 2
Blood drawn for
plasma concentration
(245 minutes)

Start HC

0 minutes

RK1/M1

RK2

RK3

RK4/M2

(75/80 minutes)

(125 minutes)

(175 minutes)

(225/230 minutes)

60 minutes

120 minutes

Pre sensitization
baseline M0

Drug
administration

(−20 minutes)

(95 minutes)

180 minutes

240 minutes

Figure 1 Timeline of training and study sessions. The procedures performed in each session are illustrated. (A) screening/training day and (B) study days.
Notes: In the control group there was no drug administration, and additional sets of the same measurements described below (M) were taken after RK2 and RK3. In the
gabapentin/placebo group, on session 1 and 2, subjects were randomly assigned to receive gabapentin or placebo. M refers to a set of measurements (mapping of area of
hyperalgesia/allodynia, heat pain detection threshold, pain during thermal stimulation).
Abbreviations: HC, heat/capsaicin sensitization; RK, rekindling.

to receive placebo or gabapentin on their first study session
by a computer generated randomization table. Subjects and
investigators directly involved in data collection and analysis
were blinded to the treatment allocation. The randomization
sequence was provided by the investigational pharmacy,
and a research nurse not directly participating in the study
managed the schedule and assigned subjects to interventions.
Of the 15 subjects who completed Part B, one subject was
excluded from the analysis because the blood sample collected on the placebo day contained gabapentin, indicating a
possible confusion in the blood sample analysis or erroneous
administration of gabapentin on the placebo day. A flow
diagram of enrollment and allocation of subjects in the study
is shown in Figure 2.
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Study measurements and procedures
All study procedures were maintained identical to the original
protocol16 and performed by the same investigator (KF) in
a quiet environment, at controlled room temperature, with
subjects comfortably sitting in a hospital bed or recliner
with armrests.

Heat/capsaicin sensitization procedure
Thermal stimulations were applied in a precise and controlled manner using a Medoc Advanced Thermal Stimulator
(Medoc Ltd., Ramat Yishai, Israel) driving a 9 cm2 thermode.
An area of the skin on the volar surface of the dominant
forearm of each subject was chosen, and the distance of the
center of this area from the elbow crease and from the wrist
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held at 40°C for 5 minutes. Subjects rated their pain on a
continuous VAS during rekindling.

49 subjects screened

17 excluded at screening*

2 excluded for HPDT >47°C on session 1

15 enrolled in Part A
15 enrolled in Part B
Randomization

8 to receive
gabapentin
in session 1

7 to receive
placebo
in session 1

1 excluded from analysis
(gabapentin found in plasma
on placebo session day)

Figure 2 Enrollment and allocation of participants in the study.
Note: *Reasons for exclusions on screening day: 5= HPDT .47°C; 9= unable to
achieve sensitization (area); 1= admitted history of drug abuse; 1= showed lesions
on forearm at physical examination; 1= body mass index .33.
Abbreviation: HPDT, heat pain detection threshold.

crease was recorded to keep the site of the area consistent
between sessions. Heat was applied to this previously delimited area using the thermode, which ramped from 32°C to
45°C at a rate of 1°C per second and then held at 45°C for
5 minutes. During these 5 minutes, subjects used an electronic handheld device to rate their pain every minute by
moving a bar on a 0–10 visual analog scale (VAS), where
0 indicates “no pain” and 10 indicates “the most intense
pain imaginable.” The handheld device was connected to a
computer that recorded the ratings on a 0–100 scale. The
heating procedure was followed by immediate application of
capsaicin cream (Capzasin-HP cream [previously 0.075%,
now marketed as 0.1%], Chattem Inc., Chattenooga, TN,
USA) covering the heated surface (outline of thermode).
The cream was left on for 30 minutes and then gently wiped
off in one single motion, taking care in avoiding rubbing
the cream into the skin. Approximately 0.5 oz of cream was
required to cover the entire surface completely. Subjects were
asked to rate their pain on the handheld VAS at the start of
the 30 minute period and then for every 5 minutes until the
cream was removed.

Rekindling
On study days, hypersensitivity was maintained by
“rekindling” the site of heat/capsaicin application. This
was accomplished by restimulating the previously treated
skin four times at 45-minute intervals with the thermode
increasing from 32°C to 40°C at a rate of 1° per second and

Journal of Pain Research 2013:6

Mapping of areas of hypersensitivity
The borders of secondary allodynia and hyperalgesia were
mapped using a 1 inch foam brush and a 26 g VF filament
(26 g bending force [North Coast Medical, Gilroy, CA,
USA]). Subjects were asked to close their eyes while the
brush was applied along four linear paths between the thermode outline and: 1) the antecubital fossa; 2) the wrist; 3)
the lateral forearm; and 4) the medial forearm. Stimulation
was started distant from the borders of the heated area and
worked closer in 5 mm steps at 1-second intervals. Subjects
were instructed to recognize a “distinct change in sensation” such as “increased burning, tenderness, more intense
pricking, or an unpleasant sensation,” and that location was
marked. This procedure was then repeated with the VF filament. Areas of hypersensitivity were calculated (in cm2) as
the distance between the farthest points marked on the rostral/
caudal axis multiplied by the distance between the farthest
points marked on the medial/lateral axis. The presence of
cutaneous hypersensitivity was assessed before the induction
of sensitization (M0 in Figure 1A and B), after RK1 (M1 in
Figure 1B), and after RK4 (M2 in Figure 1B). Two additional
measurements (after RK2 and after RK3) were taken in Part
A of the study.

Heat pain detection threshold
The threshold for heat pain detection was determined by using
a thermal ramp protocol on the marked location on the volar
surface of the forearm. The temperature applied through the
thermode was increased from 32°C to the 50°C safety cutoff
at 1°C per second. Subjects were asked to turn off the heated
thermode by depressing a button at “the lowest temperature
that they perceived as painful.” Four thermal ramps were
performed 10 seconds apart and their median value was
calculated. To avoid testing individuals whose pain threshold
approached the safety cutoff, subjects with HPDTs greater
than 47°C were excluded from the study. HPDT was assessed
before the induction of sensitization (M0 in F
 igure 1A
and B), after RK1 (M1 in Figure 1B), and after RK4 (M2 in
Figure 1B). Two additional measurements (after RK2 and
after RK3) were taken in Part A of the study.

Pain during thermal stimulation
Acute pain was induced by a 1-minute 45°C heat stimulus on
a marked location on the upper nondominant arm (deltoid).
Subjects were asked to rate their pain intensity during the
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1-minute heat stimulus continuously using the electronic
VAS, as described above. PTS was assessed before the
induction of sensitization (M0 in Figure 1A and B), after
RK1 (M1 in Figure 1B), and after RK4 (M2 in Figure 1B).
In Part A of the study, PTS was also assessed after RK2 and
after RK3.

Measurement of plasma concentration of gabapentin
All subjects in the drug/placebo group had a blood sample
(5 mL) collected from the nondominant arm to assess
gabapentin plasma concentration at 150 minutes after drug/
placebo administration (for preservation of blinding in the
protocol, the sample was collected in both sessions). Plasma
was frozen for later analysis.
Gabapentin was quantitated using LC/MS/MS (liquid
chromatography and tandem mass spectrometry). Plasma
samples were thawed, vortexed, and aliquots of 475 µL of
sample, standard or quality control sample, were transferred
into a deep well 96-well plate. To each well were added
0.25 mL of 1 M sodium phosphate buffer and 25 µL of
a 0.5 µg/mL Gabapentin D10 internal standard solution
prepared in water (Sigma-Aldrich, St Louis, MO, USA).
Samples, standards, and quality controls were then applied
to a Bond Elut C18 solid phase extraction plate (Agilent
Technologies, Böblingen, Germany), which had been prepared by washing first with 1.0 mL of methanol and then with
1.0 mL of 1 M sodium phosphate buffer. After applying the
samples to the extraction plate it was washed with 1.0 mL
of 0.1 M sodium phosphate buffer and then with 1.0 mL of
0.1 M hydrochloric acid. Samples were eluted with 1.0 mL
of methanol and the plate dried down at 30°C under a gentle
flow of nitrogen. Samples were reconstituted with 500 µL of
mobile phase: 95% 4.5 mM ammonium acetate in water/5%
4.5 mM ammonium acetate in acetonitrile. The deep well
plate was shaken for 10 minutes and 200 µL was transferred
to a 96-well autosampler plate. Calibrators (8 concentrations
over the range 0.5 to 50 ng/mL) and three quality control
samples (3, 15, and 30 ng/mL) in human plasma were prepared along with experimental samples.
Instrumental analysis was performed on an API 4000
QTRAP triple-quadropole mass spectrometer (Life Technologies, Carlsbad, CA, USA) equipped with a Turbo IonSpray
Source. A Shimadzu UFLC system (Shimadzu Corporation, Kyoto, Japan) that consisted of a CMB-20A system
controller, two LC-20ADXR pumps, a DGU-20A3 degasser, a SIL-20AC autosampler, and a CTO-20A column oven
was used to deliver the samples to the detector. An external
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two-way Valco valve (Valco Instruments Co. Inc., Houston,
TX, USA) was utilized to direct high-performance liquid
chromatography flow to waste before and after column
elution of analytes of interest. Chromatographic separation was performed on a Kinetix 2.6 µm C18 analytical
(2.1 by 100 mm) column (Phenomenex Inc., Torrance, CA,
USA) with a Security Guard ULTRA C18 guard cartridge
for 2.1 mm ID columns installed prior to the analytical
column (Phenomenex). Before each injection, the needle
was washed with 10% isopropanol. Mobile phase A was
4.5 mM ammonium acetate in water and mobile phase B
was 4.5 mM ammonium acetate in acetonitrile. Mobile
phase was delivered at initial conditions of 5% B at a flow
rate of 0.3 mL/minute with the following time program: hold
at 5% B for 0.6 minutes followed by a linear gradient over
0.65 minutes between 5% and 95% B; hold at 95% B for
1.25 minutes; mobile phase composition is then brought back
down to initial condition of 5% over 0.01 minutes. The column was re-equilibrated with 5% B from 2.51 to 4.0 minutes.
The retention time for gabapentin was 2.2 minutes under
these conditions. Both Q1 and Q3 quadrupoles of the mass
spectrometer were optimized to unit mass resolution. The
instrument was operated in positive-ion mode with an ion
spray voltage of 5,500 volts and a temperature of 450°C.
The curtain gas was set at 20 pound per square inch (psi),
ion source gas 1 at 30 psi, gas 2 at 40 psi, and the collision
gas was set to medium. Gabapentin and the internal standard were detected by multiple reaction monitoring, using
the transitions m/z 172→137 and 182→104, respectively.
Quantitation was performed in Analyst software version
1.5.2 (Life Technologies).

Statistical analysis
Our primary outcome measure was the size of the areas of
hyperalgesia to punctate stimuli (VF filament stimulation)
and dynamic tactile allodynia (brush stimulation) outside
the area directly exposed to heat and capsaicin, ie, the areas
of secondary hyperalgesia. Secondary outcome measures
included HPDT in the area directly stimulated with heat and
capsaicin (ie, the area of primary hyperalgesia), painfulness
of the rekindling procedures quantified by visual analog scale
(handheld device on a 0–10 scale translated in electronic VAS
on a 0–100 scale), and painfulness of a one minute 45°C
stimulation in normal skin (pain during thermal stimulation,
PTS as quantified by VAS).
Data were analyzed with Analyse-it (Analyse-it
Software, Ltd., Leeds, UK) version 2.26. Appropriate data
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transformations and nonparametric methods were used as
indicated. Measurements of areas of hypersensitivity were
normalized for each subject using the baseline measurements, so that the final outcome is expressed as the percent
of baseline area. Measures of area changes, HPDT, and
VAS during thermal stimulation (PTS) are expressed as
medians as well as 1st and 3rd quartiles of the values for
each subject at each chosen time point. Measures of VAS
during rekindling procedures are expressed as mean and
standard deviation. Comparisons of data sets were performed
with Student’s t-test and Wilcoxon test for paired data, and
one-way ANOVA and Friedman test for repeated measures.
A P less than 0.05 was considered statistically significant.
For all analyses, careful attention was given to whether the
data satisfied the distributional and model-specific assumptions of the procedures used.

Results
Areas of secondary hypersensitivity
to VF and foam brush stroke stimulation
Study sessions (Parts A and B)

Areas of hypersensitivity to VF stimulation and brush stroke
and red flare as expected were obtained after sensitization
with heat and capsaicin in all subjects in both Parts A and B of
this study. However, in contrast to what has been previously
reported,1,10,16 it was not possible to maintain these areas as
stable with rekindling procedures throughout the study day.
The areas of hypersensitivity tended to fade spontaneously
in the absence of pharmacological intervention (Part A), and
no significant difference was observed in reduction of areas
of secondary hyperalgesia and allodynia after treatment with
gabapentin compared to placebo (Part B).
After gabapentin administration, post-RK4 (M2 in
Figure 1B), the areas of secondary hyperalgesia to VF stimulation and allodynia to brush stroke were reduced to 65%
(34.3%–85.3%) and 32.8% (0%–76.7%), respectively, of the
areas measured at post-RK1 (M1 in Figure 1B). After placebo
administration, areas mapped by VF stimulation and brush
stroke were reduced to 78.4% (46.4%–84.9%) and 42.9%
(34.6%–56.2%), respectively. Similar results were observed
in the control group (Part A) that did not receive either placebo or drug (in Session 1, post-RK4 VF areas were reduced
to 56% [34.6%–87%] of post-RK1 area, and brush areas
were reduced to 40.3% [31.6%–79.6%] of post-RK1 area. In
Session 2, VF areas were reduced to 67.1% [41.5%–86.2%],
and brush areas were reduced to 55% [22.5%–73.3%%]).
These reductions of the areas of hypersensitivity were not
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significantly different between treatment sessions in any
group (Figure 3A–D).

Heat pain detection thresholds
HPDTs were measured to evaluate increased heat sensitivity
in the area of primary sensitization. HPDTs at M0 (Figure 1B)
were not different between sessions in any group.

Training session
On the training day, subjects enrolled both in Part A and Part
B of the study showed significantly decreased HPDTs immediately after induction of sensitization with heat and capsaicin
(M-test in Figure 1A) compared to baseline presensitization
(P,0.0001 and P,0.0004 for subjects in Part A and Part
B, respectively).

Study sessions
Part A
In the control group, baseline HPDTs before sensitization
(M0 in Figure 1B) were not different between treatment
sessions (P=0.8). HPDTs postsensitization were not different from M0 at any time point (post-RK1 through RK4),
or in any of the two study sessions (Session 1 P=0.16 and
Session 2 P=0.09).
Part B
In the gabapentin/placebo group, baseline HPDTs before sensitization (M0 in Figure 1B) were also not different between
treatment sessions (P=0.58).
After RK1 (M1 in Figure 1B), HPDTs were significantly
lower than M0 in the placebo session (P=0.03), but were
not significantly different to M0 in the gabapentin session
(P=0.28). On the placebo day, post-drug HPDTs (M2 in
Figure 1B) showed no difference with M1 (P=0.9) and
remained significantly lower than M0 (P=0.002) (Figure 4).
In the gabapentin session, post-drug HPDT measurements
at M2 were not different compared to both M0 and to M1
(P=0.08 and P=0.7, respectively).
Post-drug (M2) HPDTs were not significantly different in
the gabapentin session compared to the placebo session (41.7°C
[40.8°C–42.8°C] versus 41.4°C [40.6°C–42.4°C]; P=0.41).

VAS scores during rekindling procedures
Study session (Part A and Part B)
In both Part A and Part B of the study, pain reported by subjects during RK1 and RK4, respectively, remained constant
throughout the 5 minute procedure in both sessions (analysis
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No treatment (part A – control group)

Area of secondary hyperalgesia
(to VF stimulation)
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Treatment group (part B – gabapentin or placebo)

Area of secondary allodynia
(to brush stimulation)
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(to VF stimulation)
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P=0.58

0

Gabapentin
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Figure 3 Areas of secondary hyperalgesia and allodynia.
Notes: Percentage change of area size after treatment in the placebo/gabapentin group and at the same time-point, after the fourth rekindling, in the control group (M2)
compared to baseline (M1); data are presented as medians, 1st, and 3rd quartiles; P-values refer to comparison of percentage changes in VF and brush areas between sessions
(control group) and between treatments (placebo/gabapentin group). A P-value less than 0.05 was considered statistically significant.
Abbreviations: RK, rekindling; VF, von Frey.

was performed with one-way ANOVA to test for differences of VAS over time; 5 time-points, 1 minute apart, were
considered). In the absence of significant differences in VAS
scores recorded in the course of the 5 minutes, it was decided
to use cumulative mean VAS scores obtained during RK1 and
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RK4 to evaluate potential differences between groups (mean
VAS score during RK1 and RK4) and within group (mean
VAS score at RK1 versus mean VAS score at RK4).
In the control group (Part A), the mean VAS score over
5 minutes at RK1 was 32 (standard deviation [SD] 20.3) in
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and capsaicin application compared to baseline (M0) at any
time point (M1 and M2). In particular, in Part B, as expected,
painfulness did not differ after placebo or gabapentin administration (P=0.13).16

Gabapentin session
Placebo session

46
#
*

Degrees centigrade

45

Plasma concentrations of gabapentin

44

#

43

*

42

Median plasma concentration measured 150 minutes after
drug administration (post-M2 in Figure 1B) was 4.3 µg/mL
(3.1–6.0 µg/mL). There was no correlation between plasma
concentration of gabapentin and reduction of areas of hyper
algesia (R2=0.003) or allodynia (R2=0.035).

Discussion

41
40

2)
(M
K4
R
st
Po

R
st
Po

Ba

se

lin

e

K1

(M

(M

0)

1)

39

Figure 4 HPDTs in the treatment group.
Notes: HPDT changes at the first and second set of measurements (M1 and M2,
respectively) are compared to presensitization baseline (M0) in the gabapentin
and the placebo sessions; data are presented as medians, 1st, and 3rd quartiles;
significantly different couples of measurements are indicated: #P=0.03; *P=0.002.
(A P-value less than 0.05 was considered statistically significant). In the placebo
group HPDTs remained significantly different than baseline at each time point after
induction of heat/capsaicin sensitization.
Abbreviations: HPDT, heat pain detection thresholds; RK, rekindling.

session 1 and 32.5 (SD 22.5) in session 2. The mean VAS
score over 5 minutes at RK4 was 15.3 (SD 15.7) in session 1
and 9.9 (SD 12.8) in session 2.
In the treatment group (Part B), the mean VAS score at
RK1 was 40.2 (SD 18) on the placebo day and 40.4 (SD 21.5)
on the gabapentin day, and the mean VAS score at RK4 was
21.3 (SD 19.8) on the placebo day and 19.7 (SD 18.3) on
the gabapentin day.
VAS scores at RK4 were significantly lower than scores
at RK1 in all sessions, independent of the treatment (or no
treatment). In particular, in Part A, both in session 1 and
session 2, VAS scores during RK4 were lower than scores
during RK1 (session 1: P,0.0025 and session 2: P,0.0009;
Figure 6A). In Part B, both on placebo and gabapentin day RK4
(post-drug) VAS scores were significantly lower than RK1 scores
(P,0.00005 and P,0.00001, respectively; Figure 6B).

PTS
Study sessions (part A and part B)
In both Part A and Part B, median and maximum pain scores
measured by VAS were not significantly different after heat
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In our study, areas of sensitization to VF and brush stimulation faded over time independent of the treatment administered (gabapentin or placebo), and also in the absence of
any treatment (control group). Interestingly, the spontaneous
fading of areas despite rekindling procedures (Figure 5)
was consistent with the previously demonstrated spontaneous decay of these areas in the absence of ongoing heat
stimulation.10 In the original study by Petersen and Rowbotham,10 in the absence of rekindling (40°C for 5 minutes
every 40 minutes for over 3 hours), the areas of secondary
hyperalgesia and allodynia “decreased steadily during the
study period, demonstrating the necessity of ongoing nociceptor input.” Indeed, in our study, the area sizes decreased
steadily despite “ongoing nociceptor input” whereas, in the
original study, rekindling procedures maintained stable areas
of hypersensitivity “for at least 4 hours” after induction of
sensitization.10
As previously observed,1,10,17,31 we also found that brush
areas were consistently smaller than VF areas at each time
point. In contrast with prior observations,10 initial areas of
hyperalgesia to VF stimulation obtained in session 2 (as
measured post-RK1) were smaller than areas obtained in
session 1 (P=0.02), while the difference in initial brush areas
between the two sessions did not reach statistical significance
(P=0.09; Figure 5). The difference in areas of hyperalgesia
between the two sessions may simply reflect the instability
of these areas, while the absence of a significant difference
in areas of mechanical allodynia between sessions may indicate a lack of power of our study to detect small differences
between these already small areas. As previously reported,
intrinsic differences in the type of applied mechanical
stimuli underlie the different behavior of the areas obtained:
brush stimulation is thought to activate mainly Aβ fibers,
whereas VF filaments stimulation probably activates mainly
Aδ fibers.10
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Figure 5 Brush and von Frey areas: spontaneous fading despite rekindling procedure in control group.
Notes: Spontaneous fading of Brush areas (A and B) and von Frey areas (C and D) despite rekindling procedures is shown in the control group. Data are presented as
medians, 1st, and 3rd quartiles. Initial von Frey areas in session 2 are significantly smaller than session 1: *P,0.02 (A P-value less than 0.05 was considered statistically
significant).
Abbreviation: RK, rekindling.

Significantly decreased HPDTs after heat and capsaicin
application confirmed the creation of primary sensitization
with this model, as previously demonstrated.10,16 However,
unlike previous reports areas of secondary hypersensitivity
were not stable. Stable areas would have been necessary to
test gabapentin’s effectiveness in suppressing established
cutaneous sensitization compared to placebo. The persistent
reduction of HPDTs after RK4 (M2) compared to baseline
presensitization (M0) in the placebo session may indicate a
tendency toward reaching an adequate intensity of stimulation to sustain the area of primary heat hyperalgesia through
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the rekindling procedures. However, a similar effect was not
present in the control group.
While the initial heat/capsaicin stimulation was sufficient
to create an area of primary hyperalgesia, characterized by
hypersensitivity to heat/pain stimulation,10,31,32 the rekindling
procedures were not adequate to maintain it.
Previous studies have demonstrated that the size of the
primary area of sensitization may be a critical factor in creating and maintaining an area of secondary sensitization to
both heat and mechanical stimulation.20,33 Three main factors seem to contribute to the development and persistence
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Figure 6 Mean VAS scores for each minute during the 5-minute RK preceding the sets of measurements M1 (RK1) and M2 (RK4).
Notes: Mean VAS scores for each minute during the 5-minute RK preceding the sets of measurements M1 (RK1) and M2 (RK4). Data are presented as means and standard
deviations. (A) Session 1 and 2 of the control group are compared; (B) Placebo day and gabapentin day of the treatment group are compared. In both groups and both
study sessions, painfulness at each minute of the rekindling procedures decreased significantly between the first and fourth rekindling, despite treatment (or no treatment).
Part A: both in session 1 and session 2, VAS scores during RK4 were lower than scores during RK1 (session1: P,0.0025 and session 2 P,0.0009). Part B: both on placebo
and gabapentin day RK4 (post-drug), VAS scores were significantly lower than RK1 scores (P,0.00005 and P,0.00001, respectively). A P-value less than 0.05 was considered
statistically significant.
Abbreviations: RK, rekindling procedure; VAS, visual analog scale.

of areas of secondary sensitization: intensity of the painful
stimulation;25 duration of the noxious stimulation (continuous or repeated exposure over time);1,34,35 and size of the area
subject to primary sensitization.20,33 An adequate combination
of these three elements appears to be critical to maintain a
nociceptive input barrage strong enough to sustain central
sensitization. Establishing a “critical size” (in absolute or
even relative terms) to obtain a “sensitization outcome” of a
predictable duration and magnitude with this model – similar
to the Minimal Erythema Dose utilized by Gustorff et al in
the UVB burn model9,36 – may prove difficult due to the contribution of multiple factors to this effect (including time of
exposure, intensity of the two noxious stimuli, and intrinsic
characteristics of the subject).9,37,38 However, much like it
has been hypothesized for secondary hyperalgesia to heat,33
the development and persistence of secondary hyperalgesia
to mechanical stimulation in this experimental model seems
to critically depend on the magnitude and intensity of the
stimulation in the area of peripheral sensitization.39
Yucel et al could not confirm stable areas of secondary
hyperalgesia and allodynia by associating heat pre- and
postconditioning to topical capsaicin application.20 In Yucel
et al’s study, conditioning with heat in an attempt to “rekindle
the spontaneous afferent C-fiber input” did not have any
effect on the ongoing pain ratings and sensory test results
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(VF and brush stimulation).20 Use of a smaller probe, shorter
rekindling, and lower temperatures than utilized by Petersen
and Rowbotham10 were examined by the authors as possible
causes of failure to obtain stable areas of hypersensitization.
They observed that “the duration and stability of secondary
hyperalgesia seems to depend on both the intensity of the
initial stimulus and on continued nociceptive input.”20 Our
findings are consistent with this observation.
In the absence of sufficient ongoing nociceptive input,
areas of secondary hyperalgesia rapidly and spontaneously
decline,32 making it difficult to appreciate potential differences between treatments aimed at reducing these areas as
the differences, proportionally, tend to become smaller over
time. Indeed, in our study, areas of secondary hyperalgesia at
baseline were smaller than areas previously obtained with this
model using larger thermal probes for induction. Our average
VF areas tested immediately after induction of heat/capsaicin
sensitization (M-test in Figure 1A) were 85 cm2 for female
subjects (groups pooled, n=16) and 78 cm2 for male subjects
(n=14); brush areas were 43 cm2 for females and 48 cm2 for
males. These areas were significantly smaller than the areas
obtained from a series of studies conducted with a larger
heated probe (15.7 cm2 surface area thermode [Medoc TSA
2001; Medoc Ltd.]).40 Data from these studies were pooled
to explore gender differences and analyzed by Jensen and
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Petersen. In 85 healthy subjects (41 females/44 males) the
mean VF areas were 126 cm2 for female and 153 cm2 for
males, and the mean brush area was 107 cm2 for females
and 112 cm2 for males.40
The area of secondary hyperalgesia at baseline has been
considered a determinant of assay sensitivity in the intra
dermal capsaicin model.22 Using this model to evaluate the
effect of different treatments on capsaicin induced secondary
hyperalgesia and allodynia, Wang et al found that increasing
precision for discrimination of active treatment from placebo
was associated with increasing the area of secondary hyperalgesia at screening of the subjects.22
Our selection criteria for healthy volunteers, study procedures, and all other measurable variables, other than the
smaller size thermode, were consistent with those used in
prior placebo-controlled studies in which the model created
stable, long-lasting areas of hypersensitivity and secondary
hyperalgesia, adequate to test the effect of different drugs
on experimental cutaneous hyperalgesia.2,15,16 Therefore, our
hypothesis is that the main contributing factor to our inability
to maintain stable areas of sensitization was the relatively
undersized thermode, which produced smaller areas of hypersensitivity, and failed to produce adequate nociceptive input
to maintain these areas through the rekindling procedures.
When this smaller thermode is used to produce cutaneous sensitization in association with capsaicin, a sufficient
ongoing nociceptive input might be provided by prolonging
exposure to capsaicin28 or increasing the number and frequency of the rekindling procedures. In a functional magnetic resonance imaging (fMRI) study on pharmacological
modulation of pain-related brain activity during normal and
central sensitization states, Iannetti et al28 utilized the 9 cm2
thermode to produce heat/capsaicin cutaneous sensitization
on the shin area of the legs of 12 healthy male volunteers.
The main finding of this study is that gabapentin has a major
modulatory effect on fMRI brain responses to nociceptive
inputs during central sensitization.28
In contrast to our study, Iannetti et al28 administered
gabapentin before induction of sensitization, and heat and
capsaicin were applied at the time of the expected plasmatic
peak of gabapentin. In addition, the fMRI scan was started
only 1 hour after induction of the model, and the capsaicin
cream was not removed from the skin until the end of the
scanning period, resulting in a total time of capsaicin application of approximately 100 minutes versus 30 minutes in
the study reported here. In these conditions, which were
modified from the original model, the cutaneous sensitization was maintained by extending the exposure to capsaicin.
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The effects of gabapentin in modulating brain activity in
enhanced pain states were evaluated by fMRI activity during this “prolonged induction” phase, and no rekindling
procedures were performed to maintain the sensitization
after this initial phase.
Baseline pain measured with VAS during PTS on the
nondominant upper arm (LTS [long thermal stimulation] in
the original study by Dirks et al)16 was not different between
groups on the training day nor on any of the study days. Pain
scoring was not significantly different after heat and capsaicin
application compared to baseline (pre-heat/capsaicin application) in any group, and, as expected,16,41 painfulness did not
differ after placebo or gabapentin administration. Similarly,
in the area of primary sensitization, no difference was noted
in pain scores obtained during matched rekindling procedures
between sessions (eg RK1 versus RK1 in different study
days), and, regardless of the treatment, VAS scores during
RK4 were lower than VAS scores during RK1.
Arguably, our plasma concentrations of gabapentin
(average 4.3 µg/mL) might have been too low to detect a
significant effect of gabapentin compared to placebo in our
conditions.41,42 However, our concentrations were in the
range of therapeutic plasma concentrations (2–15 µg/mL),
and the route, dose, and administration schedule that we used
were consistent with the original protocol that we sought
to reproduce,16 where gabapentin demonstrated significant
antihyperalgesic efficacy.
Since we did not have a comparably sized thermode as
described in prior studies, we were not able to test whether
we could reproduce the model with a larger thermal probe.
Indeed, the fact that larger heating probes are not currently
commercially available was one of the reasons why we were
interested in assessing whether a smaller probe could reproduce reported results obtained with this model.

Conclusion
The ability to create long-lasting and stable areas of sensitization set the heat/capsaicin model apart from other
models of experimental cutaneous sensitization, and made
it suitable to study reversal of established hyperalgesia. The
heat/capsaicin model, as originally proposed, has become
widely popular, and extensively reported and utilized in pain
research. However, size, duration, and intensity of noxious
stimulation have been shown to be critical for the induction and maintenance of areas of secondary hyperalgesia in
multiple conditions. In our experimental setting, all other
controllable variables were consistent with the original protocol that we were seeking to replicate, except for the use of
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a smaller size thermode, and, in these conditions, we could
not confirm previous findings of a significant difference
between gabapentin and placebo in reducing areas of heat/
capsaicin induced cutaneous sensitization. We hypothesized
that the reduction in area of sensitization observed after
placebo might depend on a spontaneous fading of the area
as opposed to a “placebo effect”, which had not been previously observed.
To our knowledge, this is the first study demonstrating
the inability to reproduce the original heat/capsaicin cutaneous sensitization model by applying the critical “ongoing
nociceptive input” on a smaller surface area than originally
reported. Additionally, we hope that our negative result will
bring focus on the significant issue of standardizing and
validating experimental pain models. The advancement of
translational pain research strictly depends on the availability
of experimental pain models and methods that can be easily
and consistently reproduced, so that they can be uniformly
applied and provide results that are significant, predictive of
clinical efficacy, and comparable among different studies.
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